Centogene Stock Forecast, Price & News

-0.14 (-1.38 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume90,412 shs
Average Volume59,462 shs
Market Capitalization$199.21 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CNTG News and Ratings via Email

Sign-up to receive the latest news and ratings for Centogene and its competitors with MarketBeat's FREE daily newsletter.

Centogene logo

About Centogene

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.35 out of 5 stars

Medical Sector

816th out of 2,100 stocks

Medical Laboratories Industry

14th out of 40 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Centogene (NASDAQ:CNTG) Frequently Asked Questions

Is Centogene a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Centogene in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Centogene stock.
View analyst ratings for Centogene
or view top-rated stocks.

What stocks does MarketBeat like better than Centogene?

Wall Street analysts have given Centogene a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Centogene wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Centogene?

Centogene saw a increase in short interest in May. As of May 28th, there was short interest totaling 257,800 shares, an increase of 25.1% from the May 13th total of 206,100 shares. Based on an average trading volume of 45,100 shares, the short-interest ratio is presently 5.7 days. Currently, 4.7% of the company's shares are short sold.
View Centogene's Short Interest

When is Centogene's next earnings date?

Centogene is scheduled to release its next quarterly earnings announcement on Wednesday, September 22nd 2021.
View our earnings forecast for Centogene

How were Centogene's earnings last quarter?

Centogene (NASDAQ:CNTG) announced its quarterly earnings data on Tuesday, June, 15th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. Centogene had a negative trailing twelve-month return on equity of 38.38% and a negative net margin of 15.78%.
View Centogene's earnings history

How has Centogene's stock price been impacted by Coronavirus (COVID-19)?

Centogene's stock was trading at $18.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CNTG stock has decreased by 46.6% and is now trading at $10.03.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CNTG?

4 brokerages have issued twelve-month target prices for Centogene's stock. Their forecasts range from $14.00 to $22.00. On average, they anticipate Centogene's share price to reach $18.33 in the next year. This suggests a possible upside of 82.8% from the stock's current price.
View analysts' price targets for Centogene
or view top-rated stocks among Wall Street analysts.

Who are Centogene's key executives?

Centogene's management team includes the following people:
  • Mr. Richard Stoffelen, CFO, MD & Member of Management Board (Age 54, Pay $857.95k)
  • Dr. Volkmar Weckesser Ph.D., Chief Information Officer & Member of Management Board (Age 53, Pay $615.96k)
  • Dr. Andrin Oswald Ph.D., M.D., Member of Management Board, CEO & MD (Age 49)
  • Dr. Philip Lambert M.A., Ph.D., Chief Scientific Officer (Age 52)
  • Mr. Christoph de Artiagoitia, Sr. VP of Fin. & Admin.
  • Mr. Sun Kim M.A., Ph.D., Chief Strategy & Investor Relations Officer (Age 49)
  • Mr. Angelos Baxevanis, Sr. VP of Communication & Marketing
  • Mr. Robert W. de Deugd, Sr. VP of Sales
  • Mr. Marco Steinig, Director of HR
  • Mr. Florian Vogel Ph.D., Chief Process Officer

Who are some of Centogene's key competitors?

What other stocks do shareholders of Centogene own?

When did Centogene IPO?

(CNTG) raised $60 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Evercore ISI served as the underwriters for the IPO and Baird and BTIG were co-managers.

What is Centogene's stock symbol?

Centogene trades on the NASDAQ under the ticker symbol "CNTG."

Who are Centogene's major shareholders?

Centogene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Platinum Investment Management Ltd. (2.24%), BlackRock Inc. (2.18%), Millennium Management LLC (1.52%), Northern Trust Corp (0.45%), Victory Capital Management Inc. (0.34%) and Walleye Capital LLC (0.33%).

Which institutional investors are selling Centogene stock?

CNTG stock was sold by a variety of institutional investors in the last quarter, including Walleye Capital LLC, Northern Trust Corp, Morgan Stanley, Nuveen Asset Management LLC, and Victory Capital Management Inc..

Which institutional investors are buying Centogene stock?

CNTG stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Platinum Investment Management Ltd., BlackRock Inc., and JPMorgan Chase & Co..

How do I buy shares of Centogene?

Shares of CNTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Centogene's stock price today?

One share of CNTG stock can currently be purchased for approximately $10.03.

How much money does Centogene make?

Centogene has a market capitalization of $199.21 million and generates $146.64 million in revenue each year. The company earns $-24,490,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis.

How many employees does Centogene have?

Centogene employs 660 workers across the globe.

What is Centogene's official website?

The official website for Centogene is

Where are Centogene's headquarters?

Centogene is headquartered at AM STRANDE 7, ROSTOCK 2M, 18055.

How can I contact Centogene?

Centogene's mailing address is AM STRANDE 7, ROSTOCK 2M, 18055. The company can be reached via phone at 49-3818-011-3500 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.